Now showing items 1-20 of 31

    • canSAR: an integrated cancer public translational research and drug discovery resource. 

      Halling-Brown, MD; Bulusu, KC; Patel, M; Tym, JE; Al-Lazikani, B (2012-01)
      canSAR is a fully integrated cancer research and drug discovery resource developed to utilize the growing publicly available biological annotation, chemical screening, RNA interference screening, expression, amplification ...
    • canSAR: an updated cancer research and drug discovery knowledgebase. 

      Tym, JE; Mitsopoulos, C; Coker, EA; Razaz, P; Schierz, AC; Antolin, AA; Al-Lazikani, B (2016-01)
      canSAR (http://cansar.icr.ac.uk) is a publicly available, multidisciplinary, cancer-focused knowledgebase developed to support cancer translational research and drug discovery. canSAR integrates genomic, protein, ...
    • canSAR: update to the cancer translational research and drug discovery knowledgebase. 

      Mitsopoulos, C; Di Micco, P; Fernandez, EV; Dolciami, D; Holt, E; Mica, IL; Coker, EA; Tym, JE; Campbell, J; Che, KH; Ozer, B; Kannas, C; Antolin, AA; Workman, P; Al-Lazikani, B (2021-01)
      canSAR (http://cansar.icr.ac.uk) is the largest, public, freely available, integrative translational research and drug discovery knowledgebase for oncology. canSAR integrates vast multidisciplinary data from across genomic, ...
    • canSAR: update to the cancer translational research and drug discovery knowledgebase. 

      Coker, EA; Mitsopoulos, C; Tym, JE; Komianou, A; Kannas, C; Di Micco, P; Villasclaras Fernandez, E; Ozer, B; Antolin, AA; Workman, P; Al-Lazikani, B (2019-01)
      canSAR (http://cansar.icr.ac.uk) is a public, freely available, integrative translational research and drug discovery knowlegebase. canSAR informs researchers to help solve key bottlenecks in cancer translation and drug ...
    • canSAR: updated cancer research and drug discovery knowledgebase. 

      Bulusu, KC; Tym, JE; Coker, EA; Schierz, AC; Al-Lazikani, B (2014-01)
      canSAR (http://cansar.icr.ac.uk) is a public integrative cancer-focused knowledgebase for the support of cancer translational research and drug discovery. Through the integration of biological, pharmacological, chemical, ...
    • ChEMBL: a large-scale bioactivity database for drug discovery. 

      Gaulton, A; Bellis, LJ; Bento, AP; Chambers, J; Davies, M; Hersey, A; Light, Y; McGlinchey, S; Michalovich, D; Al-Lazikani, B; Overington, JP (2012-01)
      ChEMBL is an Open Data database containing binding, functional and ADMET information for a large number of drug-like bioactive compounds. These data are manually abstracted from the primary published literature on a regular ...
    • Combinatorial drug therapy for cancer in the post-genomic era. 

      Al-Lazikani, B; Banerji, U; Workman, P (2012-07-10)
      Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities ...
    • A comprehensive map of molecular drug targets. 

      Santos, R; Ursu, O; Gaulton, A; Bento, AP; Donadi, RS; Bologa, CG; Karlsson, A; Al-Lazikani, B; Hersey, A; Oprea, TI; Overington, JP (2017-01)
      The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clinical ...
    • Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. 

      Cato, L; Neeb, A; Sharp, A; Buzón, V; Ficarro, SB; Yang, L; Muhle-Goll, C; Kuznik, NC; Riisnaes, R; Nava Rodrigues, D; Armant, O; Gourain, V; Adelmant, G; Ntim, EA; Westerling, T; Dolling, D; Rescigno, P; Figueiredo, I; Fauser, F; Wu, J; Rottenberg, JT; Shatkina, L; Ester, C; Luy, B; Puchta, H; Troppmair, J; Jung, N; Bräse, S; Strähle, U; Marto, JA; Nienhaus, GU; Al-Lazikani, B; Salvatella, X; de Bono, JS; Cato, AC; Brown, M (2017-08-10)
      Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ...
    • Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i>-Mutant Cancers. 

      Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; Carreira, S; Cunningham, D; O'Brien, ME; Raynaud, FI; de Bono, JS; Al-Lazikani, B; Banerji, U (2019-08)
      It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ...
    • Distinctive Behaviors of Druggable Proteins in Cellular Networks. 

      Mitsopoulos, C; Schierz, AC; Workman, P; Al-Lazikani, B (2015-12-23)
      The interaction environment of a protein in a cellular network is important in defining the role that the protein plays in the system as a whole, and thus its potential suitability as a drug target. Despite the importance ...
    • Drug discovery in advanced prostate cancer: translating biology into therapy. 

      Yap, TA; Smith, AD; Ferraldeschi, R; Al-Lazikani, B; Workman, P; de Bono, JS (2016-10)
      Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology ...
    • Evolution of kinase polypharmacology across HSP90 drug discovery. 

      Antolin, AA; Clarke, PA; Collins, I; Workman, P; Al-Lazikani, B (2021-05-27)
      Most small molecules interact with several target proteins but this polypharmacology is seldom comprehensively investigated or explicitly exploited during drug discovery. Here, we use computational and experimental methods ...
    • Genomics, bio specimens, and other biological data: Current status and future directions. 

      Rosenstein, BS; Rao, A; Moran, JM; Spratt, DE; Mendonca, MS; Al-Lazikani, B; Mayo, CS; Speers, C (2018-10)
    • JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer 

      Paschalis, A; Welti, J; Neeb, AJ; Yuan, W; Figueiredo, I; Pereira, R; Ferreira, A; Riisnaes, R; Rodrigues, DN; Jimenez-Vacas, JM; Kim, S; Uo, T; Di Micco, P; Tumber, A; Islam, MS; Moesser, MA; Abboud, M; Kawamura, A; Gurel, B; Christova, R; Gil, VS; Buroni, L; Crespo, M; Miranda, S; Lambros, MB; Carreira, S; Tunariu, N; Alimonti, A; Al-Lazikani, B; Schofield, CJ; Plymate, SR; Sharp, A; de Bono, JS (AMER ASSOC CANCER RESEARCH, 2021-02-15)
    • The kinase polypharmacology landscape of clinical PARP inhibitors. 

      Antolin, AA; Ameratunga, M; Banerji, U; Clarke, PA; Workman, P; Al-Lazikani, B (2020-02-17)
      Polypharmacology plays an important role in defining response and adverse effects of drugs. For some mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically done within the same protein ...
    • Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. 

      Campbell, J; Ryan, CJ; Brough, R; Bajrami, I; Pemberton, HN; Chong, IY; Costa-Cabral, S; Frankum, J; Gulati, A; Holme, H; Miller, R; Postel-Vinay, S; Rafiq, R; Wei, W; Williamson, CT; Quigley, DA; Tym, J; Al-Lazikani, B; Fenton, T; Natrajan, R; Strauss, SJ; Ashworth, A; Lord, CJ (2016-03-03)
      One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ...
    • Leveraging Human Genetics to Guide Cancer Drug Development. 

      Kinnersley, B; Sud, A; Coker, EA; Tym, JE; Di Micco, P; Al-Lazikani, B; Houlston, RS (2018-12)
      <h4>Purpose</h4>The high attrition rate of cancer drug development programs is a barrier to realizing the promise of precision oncology. We have examined whether the genetic insights from genome-wide association studies ...
    • A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. 

      Box, C; Mendiola, M; Gowan, S; Box, GM; Valenti, M; Brandon, ADH; Al-Lazikani, B; Rogers, SJ; Wilkins, A; Harrington, KJ; Eccles, SA (2013-07)
      <h4>Background</h4>Acquired resistance to tyrosine kinase inhibitors (TKIs) is becoming a major challenge in the treatment of many cancers. Epidermal growth factor receptor (EGFR) is overexpressed in squamous carcinomas, ...